Lord, Abbett & Co
APLS

Lord, Abbett & Co’s Apellis Pharmaceuticals APLS Stock Holding History

Lord, Abbett & Co’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-54,000
Closed -$3.17M – 519
2024
Q1 		$3.17M Buy
+54,000
New +$3.44M 0.01% 507
2023
Q3 		– Sell
-1,068,143
Closed -$97.3M – 532
2023
Q2 		$97.3M Buy
1,068,143
+163,915
+18% +$14.1M 0.34% 87
2023
Q1 		$59.6M Sell
904,228
-228,395
-20% -$13.2M 0.22% 149
2022
Q4 		$58.6M Buy
1,132,623
+186,097
+20% +$9.87M 0.21% 133
2022
Q3 		$64.6M Buy
+946,526
New +$56M 0.24% 113

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co's APLS Position: Q2 2024 in Review

Lord, Abbett & Co sold out of Apellis Pharmaceuticals (APLS) in Q2 2024, closing a stake of 54,000 shares — an estimated $3.17M sold.

Lord, Abbett & Co first reported a position in APLS in Q3 2022 and held it in 5 quarters. The position peaked at $97.3M in Q2 2023. 263 funds tracked by Wall St. Rank hold APLS as of Q2 2024.

  • Lord, Abbett & Co reported no remaining Apellis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Lord, Abbett & Co sold 54,000 Apellis Pharmaceuticals shares in Q2 2024, an estimated $3.17M.
  • Lord, Abbett & Co first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 5 quarters.
  • Lord, Abbett & Co's Apellis Pharmaceuticals position peaked at $97.3M in Q2 2023.
  • 263 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2024.

Based on Lord, Abbett & Co's 13F filing for Q2 2024, filed 14 Aug 2024.